News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
255,847 Results
Type
Article (12004)
Company Profile (63)
Press Release (243780)
Multimedia
Podcasts (12)
Webinars (4)
Section
Business (74464)
Career Advice (429)
Deals (14039)
Drug Delivery (36)
Drug Development (36701)
Employer Resources (31)
FDA (7126)
Job Trends (5383)
News (133203)
Policy (12080)
Tag
2024 BioCapital Digital (2)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (1)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (6)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (1)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (3)
2024 Pharm Country Digital (1)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (830)
Academic (1)
Accelerated approval (1)
Adcomms (7)
Allergies (31)
Alliances (18808)
ALS (45)
Alzheimer's disease (512)
Antibody-drug conjugate (ADC) (48)
Approvals (7188)
Artificial intelligence (74)
Autoimmune disease (10)
Automation (3)
Bankruptcy (77)
Best Places to Work (4412)
BIOSECURE Act (11)
Biosimilars (30)
Biotechnology (41)
Bladder cancer (28)
Brain cancer (9)
Breast cancer (132)
Cancer (1012)
Cardiovascular disease (76)
Career advice (342)
Career pathing (11)
CAR-T (57)
Cell therapy (167)
Cervical cancer (9)
Clinical research (30666)
Collaboration (339)
Compensation (491)
Complete response letters (9)
COVID-19 (914)
CRISPR (13)
C-suite (92)
Cystic fibrosis (41)
Data (1086)
Decentralized trials (2)
Depression (12)
Diabetes (127)
Diagnostics (2167)
Digital health (6)
Diversity (1)
Diversity, equity & inclusion (11)
Drug discovery (45)
Drug pricing (25)
Drug shortages (6)
Duchenne muscular dystrophy (32)
Earnings (31567)
Editorial (9)
Employer branding (5)
Employer resources (32)
Events (36172)
Executive appointments (268)
FDA (7645)
Featured Employer (30)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (3)
Funding (303)
Gene editing (36)
Generative AI (8)
Gene therapy (113)
GLP-1 (323)
Government (1466)
Guidances (21)
Healthcare (6688)
Huntington's disease (9)
IgA nephropathy (12)
Immunology and inflammation (44)
Indications (20)
Infectious disease (980)
Inflammatory bowel disease (58)
Inflation Reduction Act (2)
Influenza (29)
Intellectual property (33)
Interviews (65)
IPO (7804)
IRA (16)
Job creations (1234)
Job search strategy (311)
Kidney cancer (4)
Labor market (10)
Layoffs (206)
Leadership (5)
Legal (2350)
Liver cancer (33)
Lung cancer (183)
Lymphoma (102)
Machine learning (3)
Management (12)
Manufacturing (139)
MASH (29)
Medical device (4104)
Medtech (4104)
Mergers & acquisitions (6508)
Metabolic disorders (278)
Multiple sclerosis (23)
NASH (7)
Neurodegenerative disease (32)
Neuropsychiatric disorders (10)
Neuroscience (707)
NextGen: Class of 2025 (1963)
Non-profit (1802)
Northern California (1163)
Now hiring (14)
Obesity (131)
Opinion (94)
Ovarian cancer (33)
Pain (24)
Pancreatic cancer (34)
Parkinson's disease (52)
Partnered (9)
Patents (74)
Patient recruitment (40)
Peanut (15)
People (20778)
Pharmaceutical (16)
Pharmacy benefit managers (4)
Phase I (8725)
Phase II (13151)
Phase III (11065)
Pipeline (653)
Policy (55)
Postmarket research (1514)
Preclinical (3625)
Press Release (43)
Prostate cancer (49)
Psychedelics (10)
Radiopharmaceuticals (115)
Rare diseases (150)
Real estate (2302)
Recruiting (10)
Regulatory (9099)
Reports (13)
Research institute (826)
Resumes & cover letters (62)
Rett syndrome (1)
RSV (19)
Schizophrenia (32)
Series A (51)
Series B (25)
Service/supplier (6)
Sickle cell disease (21)
Southern California (923)
Special edition (6)
Spinal muscular atrophy (36)
Sponsored (7)
Startups (1301)
State (1)
Stomach cancer (4)
Supply chain (21)
Tariffs (11)
The Weekly (12)
United States (9373)
Vaccines (254)
Venture capitalists (16)
Weight loss (64)
Women's health (6)
Worklife (2)
Date
Today (3)
Last 7 days (207)
Last 30 days (999)
Last 365 days (14297)
2025 (3920)
2024 (15194)
2023 (16754)
2022 (22014)
2021 (22709)
2020 (20192)
2019 (16785)
2018 (12561)
2017 (11937)
2016 (10555)
2015 (12166)
2014 (8906)
2013 (7200)
2012 (8149)
2011 (9414)
2010 (9175)
Location
Africa (204)
Alabama (17)
Alaska (2)
Arizona (48)
Arkansas (1)
Asia (17015)
Australia (2300)
California (2428)
Canada (812)
China (302)
Colorado (80)
Connecticut (122)
Delaware (84)
Europe (39507)
Florida (329)
Georgia (75)
Idaho (14)
Illinois (187)
India (13)
Indiana (143)
Iowa (3)
Japan (93)
Kansas (33)
Kentucky (16)
Louisiana (3)
Maine (14)
Maryland (334)
Massachusetts (1868)
Michigan (70)
Minnesota (89)
Missouri (33)
Montana (7)
Nebraska (10)
Nevada (21)
New Hampshire (7)
New Jersey (780)
New Mexico (6)
New York (631)
North Carolina (945)
North Dakota (4)
Northern California (1163)
Ohio (92)
Oklahoma (5)
Oregon (9)
Pennsylvania (470)
Puerto Rico (2)
Rhode Island (24)
South America (400)
South Carolina (15)
Southern California (923)
Tennessee (15)
Texas (307)
Utah (66)
Virginia (37)
Washington D.C. (42)
Washington State (188)
West Virginia (1)
Wisconsin (25)
255,847 Results for "c r bard".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Evecxia Therapeutics Announces Appointment Of C.R. Sincock II To The Board Of Directors
April 10, 2025
·
1 min read
Press Releases
Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson’s Patients
Parkinson’s Patients Have Improved Motor and Non-Motor Function After Treatment with Theralase(R) Cool Laser Therapy
March 10, 2025
·
12 min read
Clinical research
Pharma R&D Returns Grow Again, But Deloitte Warns Progress is ‘Fragile’
Deloitte urged pharma executives to “be bold” in a new report tracking the top 20 pharmaceutical companies’ R&D performance.
March 27, 2025
·
3 min read
·
Annalee Armstrong
Press Releases
IND for ATA-200, a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2C/R5 (LGMD2C/R5), cleared to proceed by FDA
November 12, 2024
·
3 min read
Press Releases
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
January 22, 2025
·
11 min read
Career Advice
Computational Biology, Data Science Hot Areas for Oncology R&D Hiring
As market values increase for computational biology and data science, biopharma companies are looking to hire R&D professionals in those areas. A biotech talent acquisition expert shares his insights on these in-demand roles.
January 2, 2025
·
5 min read
·
Angela Gabriel
Press Releases
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML
April 8, 2025
·
6 min read
Press Releases
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
December 18, 2024
·
8 min read
Press Releases
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
March 20, 2025
·
16 min read
Atamyo Therapeutics Obtains Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-200, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5
Atamyo Therapeutics announced the first authorization of a Clinical Trial Application in Europe for ATA-200, its gene therapy for the treatment of the γ-sarcoglycan related limb-girdle muscular dystrophy Type 2C/R5.
March 26, 2024
·
4 min read
1 of 25,585
Next
